

April 22, 2026  
SymBio Pharmaceuticals Limited  
Fuminori Yoshida  
Representative Director  
President and Chief Executive Officer  
(Securities Code: 4582)

**Brincidofovir Shows Efficacy in Preclinical Study of EBV-Associated Gastric Carcinoma  
Poster Presentation Accepted at the ASCO Annual Meeting 2026**

**TOKYO, Japan, April 22, 2026** -- SymBio Pharmaceuticals Limited (“SymBio” or the “Company”) today announced that preclinical data on the efficacy of its antiviral agent brincidofovir (“BCV”) in Epstein-Barr virus (“EBV”)-associated gastric carcinoma (“EBVaGC”) has been accepted for a poster presentation at the American Society of Clinical Oncology (“ASCO”) Annual Meeting. The presentation will be delivered by Tetsu Kamitani, Head of Translational Research at SymBio. (Abstract Number: 4028)

This study suggests the potential of BCV as a novel therapeutic option in the treatment strategy for EBVaGC, supported by the ongoing development of BCV as an antiviral agent.

**Summary of the Presentation**

Title: Preclinical efficacy of the anti-EBV agent brincidofovir (BCV) in EBV-associated gastric carcinoma (EBVaGC)

Presenter: Tetsu Kamitani

Abstract Number: 4028

Date: May 29 – June 2, 2026

Venue: Chicago, Illinois, U.S.

Statement from Tetsu Kamitani: “This study demonstrates a new potential for BCV in an oncology setting where treatment options remain limited.”

**[Contact]**

Investor Relations

Tel: +81 (0)3 5427 1125

## Note

### 1. About EBV-Associated Gastric Carcinoma (EBVaGC)

Gastric cancer is one of the major cancers worldwide, with approximately one million new cases diagnosed each year. Approximately 10% of these are associated with EBV infection, corresponding to an estimated 90,000 cases worldwide and 13,000 cases in Japan annually. EBVaGC is a subtype of gastric cancer that arises in association with persistent EBV infection within tumor cells and is strongly influenced by EBV-derived gene expression and the host (patient) immune response. EBVaGC is not merely a clinical variant but a distinct subtype of gastric cancer involving a unique pathology driven by the interplay between EBV and the host, and understanding its molecular mechanisms and immunological characteristics is expected to lead to the development of effective therapies. Currently, no anticancer therapy specifically targeting EBVaGC has yet been established.

### 2. About the American Society of Clinical Oncology (ASCO)

Founded in 1964, ASCO is one of the world's leading professional organizations in the field of cancer treatment and research, with more than 50,000 members from over 150 countries. The ASCO Annual Meeting is one of the most important international forums for presenting the latest advances in cancer research and treatment, bringing together clinical oncologists, researchers, and healthcare professionals from around the world to share the latest knowledge.